Concepedia

Author

Arunachalam Sekar

Weizmann Institute of ScienceORCID

Also Known As

Arunachalam Sekar

38

Publications

253

Citations

8

H-Index

16

Concepts

All Affiliations

Weizmann Institute of ScienceOsaka University of Pharmaceutical SciencesThe University of OsakaUniversity of CambridgeUniversity of Bologna
AS

About

Arunachalam Sekar is an author at Weizmann Institute of Science specializing in cell biology, medicine, and lung cancer.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

59

2

Cell Biology

2

2

59

3

Natural Sciences

1

1

15

4

Molecular Biology

1

1

15

5

Pathology

1

1

44

Arunachalam Sekar

×

8

Publications

249

Citations

8

H-Index

YearCitations

AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer

Ashish Noronha, Nishanth Belugali Nataraj, Joo Sang Lee,

Cancer Discovery

2022

94

PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR

Soma Ghosh, Nishanth Belugali Nataraj, Ashish Noronha,

Cell Reports

2021

44

ETS Proteins Bind with Glucocorticoid Receptors: Relevance for Treatment of Ewing Sarcoma

Swati Srivastava, Nishanth Belugali Nataraj, Arunachalam Sekar,

Cell Reports

2019

27

Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors

Nishanth Belugali Nataraj, Ashish Noronha, Joo Sang Lee,

Cell Reports

2022

25

TSHZ2 is an EGF-regulated tumor suppressor that binds to the cytokinesis regulator PRC1 and inhibits metastasis

Mary Luz Uribe, Maik Dahlhoff, R.N. Batra,

Science Signaling

2021

17

Synthesis, characterization, and evaluation of Cd[L-proline]2, a novel histone deacetylase inhibitor that induces epigenetic modification of histone deacetylase isoforms in A549 cells

Chidambaram Anusha, Arunachalam Sekar, Kavya S.H.,

Investigational New Drugs

2017

15

L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab

Ilaria Marrocco, Suvendu Giri, Arturo Simoni‐Nieves,

Cell Reports Medicine

2023

15

Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors

Yuya Haga, Ilaria Marrocco, Ashish Noronha,

Cancer Research

2021

12

Page 1